Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433732 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches
A Phase 3 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,400
- Enrollment target
NCT00433732 is a Phase 3 study that has completed, run by POZEN. The registered enrollment target is 1,400 participants.
The verdict
NCT00433732, a Phase 3 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary endpoints.
Interventions
- DRUG sumatriptan
- DRUG naproxen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433732
The ClinicalTrials.gov registry entry for NCT00433732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sumatriptan is the first listed.
NCT00433732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00433732 about?
NCT00433732 is a clinical study titled "To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches". To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary endpoints.
What is the current status of trial NCT00433732?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,400 participants. The study started on 2004-08. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00433732?
The interventions under investigation include: sumatriptan (DRUG), naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00433732?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.